June 23rd 2025
The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.
NDA Filed for Avutometinib Plus Defactinib for Low-Grade Serous Ovarian Cancer
November 3rd 2024The FDA has received a rolling new drug application (NDA) for avutometinib plus defactinib for the treatment of adult patients with recurrent low-grade serous ovarian cancer harboring KRAS mutations who have received at least 1 prior line of systemic therapy.